ASC, Intl. announced separation into two standalone companies, ASC, Inc. and ASC Therapeutics, Inc. which is whole owned by ASC Intl. | ASC

June 15th, 2020 (Milpitas) – Applied StemCell, Intl. announced separation into two standalone companies, Applied StemCell, Inc. and ASC Therapeutics, Inc. which is whole owned by Applied StemCell Intl.
Applied StemCell Inc. will continue to conduct its legacy life science business with a goal to advance gene- editing and stem cell innovation for biomedical research, biotechnology industry and serves as a CRO for gene and cell therapy.

ASC Therapeutics, Inc. sets the goal to develop revolutionary gene and cell medicines to cure intractable diseases.
IRS Form 8937 and Instruction “ASC International Report of Organizational Action Affecting Basis of Securities”, and “Report of Organizational Actions Affecting Basis of Securities” has been provided pursuant to the requirement of Section 6045B of the Internal Revenue Code of 1986.

• Form 8937
• Report of Organizational Action 

About Applied StemCell, Inc.: Applied StemCell, Inc. is a fast-growing biotechnology company with 12 years of experience in genome editing and stem cell technologies. Our mission is to advance genome editing technology innovation to enable in vivo/in vitro preclinical study as well as serving as a CRO for gene and cell therapy. More information can be found at www.appliedstemcell.com.

Contact: Lucy Gu Director, Finance and Administration

Email: Lucy.gu@appliedstemcell.com